Related Experiment Video

Updated: Apr 28, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Myeloperoxidase gene polymorphism predicts fibrosis severity in women with hepatitis C

Rodrigo Feliciano do Carmo1, Luydson Richardson Silva Vasconcelos2, Taciana Furtado Mendonça3

  • 1Colegiado de Ciências Farmacêuticas, Universidade Federal do Vale do São Francisco, Pernambuco, Brazil; Rede Nordeste de Biotecnologia, Pernambuco, Brazil.

Human Immunology
|June 3, 2014
PubMed

Insights

The MPO GG genotype is a risk factor for liver fibrosis severity in women with Hepatitis C virus (HCV) infection. Metabolic syndrome also independently predicts fibrosis severity in this demographic.

Area of Science:

  • Hepatology
  • Genetics
  • Immunology

Background:

  • Oxidative stress significantly impacts liver fibrosis progression in Hepatitis C virus (HCV) infection.
  • Myeloperoxidase (MPO) generates reactive oxygen species (ROS) contributing to liver injury, while manganese superoxide dismutase (SOD) mitigates ROS damage.

Purpose of the Study:

  • To investigate the association between MPO G-463A and SOD2 Ala16Val gene polymorphisms and liver fibrosis severity in chronic HCV patients.
  • To identify genetic and clinical factors influencing liver fibrosis progression in HCV infection.

Main Methods:

  • Study included 270 chronic HCV patients from Northeastern Brazil, assessed via liver biopsy using the METAVIR score.
  • Single nucleotide polymorphisms (SNPs) were genotyped using real-time PCR.
  • Multivariate analysis was employed to adjust for confounding factors.

Main Results:

  • The MPO GG genotype was independently associated with increased liver fibrosis severity in women (P = 0.025, OR 2.25).
  • Metabolic syndrome was also independently linked to fibrosis severity in women (P = 0.032, OR 2.32).
  • The GG genotype of MPO appears to be a significant risk factor for fibrosis severity specifically in women with HCV.

Conclusions:

  • Genetic variations in MPO, specifically the GG genotype, are linked to more severe liver fibrosis in women with chronic HCV.
  • Metabolic syndrome is an independent predictor of fibrosis severity in women with HCV.
  • These findings highlight potential genetic and clinical markers for assessing fibrosis risk in HCV patients, particularly women.
Keywords:
FibrosisHCVMPOPolymorphismSOD

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.7K

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
337
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382